673 results about "Fatty liver" patented technology

The invention relates to the technical field of grease chemistry, in particular to a preparation method and application of diglyceride oil capable of preventing and treating fatty liver. The preparation method comprises the following steps: (1) mixing raw material oil, water, glycerol and a lipase preparation for catalytic reaction to obtain a product 1; the raw material oil comprises 0.1-8 parts of sea buckthorn seed oil, 0.1-8 parts of acer truncatum seed oil, 60-90 parts of low erucic acid rapeseed oil, 15-35 parts of corn oil and 10-25 parts of peanut oil; the lipase preparation is aspergillus niger lipase and rhizopus niger lipase; (2) performing five-stage molecular distillation on the product 1 to obtain a product 2; and (3) decoloring and deodorizing the product 2 to obtain the product. The diglyceride oil prepared by the invention has excellent effects of preventing and treating fatty liver.

The present disclosure provides a method of treating a fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.

The invention discloses pediococcus acidilactici and application thereof, and relates to the technical field of microorganisms. The pediococcus acidilactici is pediococcus acidilactici Mei.1103.1, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC NO.32564, the preservation date is November 11, 2024, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1 is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1. The invention also provides application of the fermented dry rice flour in preparation of products for reducing uric acid, preventing / treating hyperuricemia, regulating immunity, preventing / treating kidney injury and preventing / treating fatty liver and fermented dry rice flour. The bacterium can reduce uric acid and relieve hyperuricemia; regulating blood fat; kidney and liver injuries caused by hyperuricemia are repaired; the content of volatile flavor compounds in the fermented dry rice flour is increased.

The invention relates to application of mouse combined lactobacillus. According to the application disclosed by the invention, the lactobacillus murins DSM 28683 can be applied to the preparation of a product for treating type 2 diabetes mellitus or a product for reducing body fat. A T2D mouse is subjected to intragastric administration by using the Ligilbacillus murins DSM 28683, and it is found that the Ligilbacillus murins DSM 28683 can significantly improve metabolism of the T2D mouse, effectively improve insulin sensitivity of the T2D mouse, reduce body weight and improve fatty liver, and has a good application prospect in treatment of type 2 diabetes mellitus.

The present disclosure provides a method of treating a fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.

The invention belongs to the field of active peptides, and particularly relates to application of selenium-rich polypeptide in inhibiting NLRP3 inflammasome-related inflammations and regulating cholesterol transport protection lipid metabolism abnormality, the selenium-rich polypeptide is prepared by chelating Adi-Apo fusion protein as shown in SEQ ID NO: 3 and sodium selenite (Na2SeO3); the selenium peptide chelate has the effects of remarkably reducing the concentration of TC / TG in serum, reducing the liver lipid deposition and inflammation level and reducing the atherosclerotic plaque area proportion through high oxidation resistance and high anti-inflammatory activity, and can be used for treating and / or preventing lipid metabolism disorder diseases such as metabolism-related fatty liver diseases and coronary atherosclerosis.

The present disclosure relates to a once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same to induce weight loss in humans suffering from fatty liver disease, where the humans may or may not suffer from other complications, such as type 2 diabetes and / or cardiovascular disease / disorder. The dual agonist of the GLP-1R and the GCGR comprises a peptide product of SEQ ID NO. 1 (pemvidude), and a preparation method of the GLP-1R and GCGR dual agonist.

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating liver depression and spleen deficiency syndrome metabolism-related fatty liver disease, which is prepared from the following raw materials in parts by weight: 8 to 10 parts of ginseng, 10 to 15 parts of radix bupleuri, 10 to 15 parts of radix curcumae, 6 to 9 parts of ginger processed pinellia, 6 to 10 parts of fructus amomi, 10 to 15 parts of rhizoma atractylodis, 10 to 15 parts of poria cocos, 10 to 15 parts of semen hoveniae, 10 to 15 parts of radix rehmanniae, 8 to 10 parts of rhizoma polygoni cuspidati and 6 to 9 parts of lignum dalbergiae odoriferae. The traditional Chinese medicine composition is used for treating the metabolism-related fatty liver diseases from the aspects of liver depression, spleen deficiency and phlegm-blood stasis, starts from the core pathological chain of liver depression, spleen deficiency, phlegm-dampness and blood stasis, has the functions of soothing the liver, tonifying the spleen, resolving dampness, reducing fat and promoting blood circulation to remove meridian obstruction, and is particularly suitable for patients with liver depression, spleen deficiency and metabolism-related fatty liver diseases. Clinical tests prove that the traditional Chinese medicine composition has a good treatment effect on patients with liver depression and spleen deficiency syndrome metabolism-related fatty liver diseases, the total effective rate reaches 94% or above, and the traditional Chinese medicine composition is mild in medicine property, good in safety, stable in curative effect, not prone to relapse and suitable for being taken for a long time.

The invention discloses a lactobacillus mucus fermentation strain and application thereof, the lactobacillus mucus fermentation strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on February 21, 2025, and the preservation number is GDMCCNO: 65936. The feruloyl esterase is separated and screened from white sour soup in Kailing in southeast of Guizhou province, has feruloyl esterase activity, and shows good blood fat reducing and fatty liver treating capabilities in a HepG2 high-fat cell model and a high-fat zebra fish model. The compound has a good prospect in the development of products for preventing or treating hyperlipidemia and fatty liver and relieving obesity.

The invention discloses a multi-classification auxiliary prediction method and system for metabolism-related fatty liver diseases, electronic equipment and a storage medium, belongs to the field of medical data processing, and is used for solving the problem that a traditional MAFLD binary prediction model cannot fully reflect continuous pedigree of disease severity. The method comprises the following steps: acquiring clinical data related to classification prediction of metabolism-related fatty liver diseases; performing label coding, missing value filling and feature screening on the clinical data; and inputting the screened features into a TabNet classification model optimized by a particle swarm algorithm, and outputting a risk classification result of the metabolism-related fatty liver disease. According to the method, the severity of the fatty liver can be more accurately evaluated, the liver health condition of a patient is comprehensively reflected, and more accurate treatment guidance is provided for clinical diagnosis.

The invention provides a rice bran fatty alkanol composition for reducing fat and losing weight and a preparation method of the rice bran fatty alkanol composition. The rice bran fatty alkanol composition for reducing fat and losing weight is composed of rice bran fatty alkanol and soybean sterol, and the rice bran fatty alkanol accounts for 5-30% of the mass of the composition. By optimizing the fingerprint spectrum of rice bran fatty alkanol, the composition proportion of higher fatty alkanol is effectively improved, the lipid-lowering, weight-losing and liver-protecting effects can be effectively improved, the lipid-lowering, weight-losing and liver-protecting effects are greatly improved by matching with soybean sterol, and a tablet containing the composition is further developed. The obtained lipid-lowering weight-losing liver-protecting tablet is safe and free of side effects, and can be eaten for a long time to prevent obesity and fatty liver.

The invention discloses a Coprococcus eutaxus strain and an application of the Coprococcus eutaxus strain, and relates to the technical field of probiotics. According to the present invention, the Coprococcus eutactus strain is named as Coprococcus eutactus GZSY125, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, the preservation unit is Guangdong Microbial Culture Collection Center, and the address of the preservation unit is the fifth floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangdong Province, the preservation number is CGMCC No.66029, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, and the preservation number is CGMCC No.66029. The invention provides the Coprococcus eutaxus, the Coprococcus eutaxus can be used for remarkably improving liver lipid accumulation, inflammation and fibrosis, has a certain treatment effect on the metabolism-related fatty liver disease (MAFLD), provides a new treatment thought for clinically intervening the MAFLD, and has important clinical significance on the treatment of the MAFLD.

The invention discloses application of vanillyl alcohol in preparation of medicines for preventing and treating fatty liver, obesity or diabetes, and belongs to the technical field of medicines. The invention is implemented in vitro and in vivo, and aims to solve the problem of lack of low-toxicity natural small molecule drugs for effectively preventing and treating fatty liver, obesity or diabetes at present. The embodiment of the invention proves that the vanillyl alcohol can obviously reduce high-fat diet induced mouse fat deposition, reduce in-vivo and in-vitro liver TG content and lipid droplet accumulation, enhance glucose tolerance of the high-fat diet induced mouse and improve insulin resistance of the high-fat diet induced mouse. As a natural antioxidant, vanillyl alcohol has an obvious relieving effect on energy metabolism disorder and oxidative stress induced by high fat. As a low-toxicity natural small molecule, vanillyl alcohol can improve glucose and lipid metabolism disorder induced by high fat, is low in price, and has application value in preparation of medicines for preventing and treating fatty liver, obesity or diabetes mellitus.

The present invention is directed to substituted 1-(1H-imidazol-1-yl)-3-methyl-2- phenylbutan-2-ol and 1-cyclopentyl-2-(1H-imidazol-1-yl)-1-phenylethan-1-ol compounds useful as agonists of 8-oxo-guanine DNA glycosylase (OGG1) in humans, as well as pharmaceutical compositions comprising them and methods of their use in treating diseases, including metabolic syndrome, obesity, fatty liver disease, dyslipidemia, insulin resistance, neurodegenerative disorders and cancers.

The invention relates to the technical field of liver disease prediction, in particular to a metabolism-related fatty liver disease intelligent prediction method and system and a storage medium. The method comprises the following steps: collecting multi-source data, respectively obtaining basic demographic information, laboratory indexes and prediction indexes, and extracting quantitative and qualitative tongue picture parameters; performing variable screening on the tongue picture parameters and the clinical indexes, and determining key prediction variables; obtaining a key variable value according to the key prediction variable, obtaining a prediction result of the occurrence risk of the metabolism-related fatty liver disease, and outputting the prediction result; the system comprises a multi-source data acquisition module, a variable screening module and a prediction result acquisition module. By means of the mode, the intelligent tongue picture parameters and the clinical indexes are fused, and the effect of early prediction of the metabolism-related fatty liver diseases is achieved.

The invention belongs to the technical field of biological pharmacy, and provides an application of jonquil glucoside in preparation of a medicine for treating a metabolism-related fatty liver disease, and the application is that the jonquil glucoside is applied to preparation of the medicine for treating the metabolism-related fatty liver disease. The treatment effect of the jonquil glycoside on MASLD is evaluated by adopting a method for establishing a fatty liver model through induction of HFD high-fat, high-fructose and high-cholesterol feed. Results show that the jonquil glucoside can reduce the liver weight by inhibiting weight gain, reduce the content of TC and TG in serum, improve the conditions of liver inflammation and fat change, reduce the oxidative stress level of liver tissue and restore SIRT1 protein expression of the liver tissue to achieve the purpose of treating MASLD.

The invention belongs to the technical field of biological medicines, and particularly relates to a traditional Chinese medicine composition for treating metabolism-related fatty liver diseases and a preparation method thereof. The technical problem to be solved by the invention is to provide a new choice for treating metabolism-related fatty liver diseases. According to the technical scheme, the traditional Chinese medicine composition for treating the metabolism-related fatty liver disease is prepared from the following components: radix paeoniae rubra, cyrtomium fortunei, curcuma zedoary, sculellaria barbata, herba epimedii, fingered citron, semen cassiae and herba artemisiae scopariae. The invention is mainly used for providing a new choice for treating the metabolism-related fatty liver disease, and has a wide application prospect.

The invention relates to a preparation method of a silymarin and pueraria isoflavone composite reagent. The preparation method comprises the following steps: S1, extracting silybin; s2, soaking the roots and stems of the kudzuvine roots; s3, extracting a radix puerariae isoflavone stock solution; s4, concentrating the radix puerariae isoflavone stock solution; s5, extracting a pueraria isoflavone concentrated solution; s6, mixing and granulating; and S7, tabletting and coating to obtain the flaky silymarin and pueraria isoflavone composite reagent. According to the prepared silymarin and pueraria isoflavone composite reagent, the silymarin dry powder and the pueraria isoflavone extract serve as core components, the silymarin dry powder can enhance liver detoxification and repair liver cells, the pueraria isoflavone extract can accelerate alcohol metabolism, and the silymarin dry powder and the pueraria isoflavone extract have a remarkable improvement effect on fatty liver, alcoholic liver and the like under the synergistic effect.

The invention discloses a construction method of a metabolism-related fatty liver cancer (MAFLD liver cancer) mouse model, and relates to the technical field of biology. The specific construction method comprises the following steps: feeding a 7-9-week-old mouse with a high-fat and high-sugar diet for 24 weeks, inducing the mouse to form fatty liver, and causing metabolic dysfunction; injecting carbon tetrachloride into the abdominal cavity of the mouse once a week while feeding the mouse with the high-fat and high-sugar diet, and inducing the liver of the mouse to form liver cancer continuously for 24 weeks, so as to construct the MAFLD liver cancer mouse. The mouse liver constructed by the method has metabolic dysfunction, fatty liver and liver cancer lesions, and has extremely high application value in research and development of drugs for researching MAFLD liver cancer pathogenesis and fatty liver related liver cancer in the future.

The invention discloses a traditional Chinese medicine composition for treating fatty liver diseases related to metabolic dysfunction. The traditional Chinese medicine composition is prepared from the following raw material medicines: Qu fructus aurantii, lotus leaves, semen cassiae, gynostemma pentaphylla, rhizoma alismatis, rhodiola rosea, radix salviae miltiorrhizae, pseudo-ginseng and rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition and the traditional Chinese medicine compound preparation disclosed by the invention can improve the blood sugar and blood fat levels of fatty liver diseases related to metabolic dysfunction and improve the metabolic level, are remarkable in clinical curative effect, improve the living quality of patients, have the effects of regulating qi, soothing the liver, tonifying the spleen and removing stasis, slow down liver fibrosis by improving blood sugar and blood fat metabolism, and are quick in curative effect and low in price.

The invention provides a new target for treating metabolism-related fatty liver diseases, a regulation molecule and application thereof. The invention discloses a novel target gene closely related to relieving or treating the metabolism-related fatty liver disease and a signal channel related to upstream and downstream regulation and control of the target gene for the first time. The invention discloses a new mechanism participated by the signal channel and used for regulating and controlling the metabolism-related fatty liver disease. Preferred remission / therapeutic agents are also disclosed.

The present invention belongs to the technical field of drug or functional food application. The present invention discloses a compound of the following structural formula and the use of the compound in preparing a drug for treating fatty liver disease or a functional food for alleviating fatty liver disease. Also disclosed is Eurotium cristatum ( Eurotium cristatum )SXHBTBU1934 and a method for preparing the compound.

The invention discloses a multi-classification risk prediction method and system for liver diseases based on machine learning, and relates to the technical field of biomedicine, and the method comprises the following steps: collecting fatty liver disease diagnosis results and biochemical indexes of a subject to form a training sample set, the method comprises the following steps: screening out biochemical indexes significantly related to fatty liver diseases through single-factor regression analysis, determining potential risk factors, carrying out multicollinearity test on the factors, screening out risk factors, constructing a plurality of machine learning classification models for training, and selecting a model with the best performance as a reference model. The contribution degree of each important risk factor is evaluated and sorted, classification significant factors are determined, the significant factors serve as classification metadata, a plurality of judgment models are trained, input factors are dynamically selected according to contribution values, and finally a fatty liver disease degree classification result is output, so that complex conditions under different sample features and clinical backgrounds are better handled; and the accuracy of prediction results is improved.

The present invention relates to the application of a silymarin pharmaceutical composition in the preparation of a drug for treating fatty liver disease, and belongs to the field of medical technology. The present invention provides the application of a pharmaceutical composition in the preparation of a drug for preventing and / or treating fatty liver disease, wherein the active ingredient of the pharmaceutical composition comprises a 7-KDCA regulator; the 7-KDCA regulator comprises silymarin, or the 7-KDCA regulator comprises silybin, silybin, silybinin and / or isosilybin; the silybin comprises silybin A and / or silybin B; the isosilybin comprises isosilybin A and / or isosilybin B. Studies have shown that the pharmaceutical composition can effectively and safely treat fatty liver disease at a low dose, has anti-inflammatory activity, and has a mimetic nerve growth factor activity, and has great application prospects in the preparation of drugs for preventing and / or treating fatty liver disease, anti-inflammatory, and preventing and / or treating Alzheimer's disease.

The invention belongs to the technical field of biology, and discloses a strain of eurotium cristatum, the classification name of the eurotium cristatum is eurotium cristatum, and the preservation number of the eurotium cristatum is CGMCC (China General Microbiological Culture Collection Center) NO: 40145. The preservation date is March 10, 2022, the preservation unit is China General Microbiological Culture Collection Center, and the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. After the strain is used for fermenting the Yingde black tea, a characteristic peak appears at the position of 2min on a chromatogram, the content of the characteristic peak is obviously higher than the peak area of chromatograms of black tea fermented by other strains, and the strain has potential obvious effects of reducing blood fat and relieving fatty liver after acting on the Yingde black tea. Meanwhile, the invention also provides application of the strain.

The invention provides a nano-drug delivery system for treating fatty liver based on liposome, exosome and metal organic framework synergistic targeting and a preparation method of the nano-drug delivery system, and relates to the technical field of novel nano-material preparation, the nano-drug delivery system comprises liposome, mesenchymal stem cell exosome and metal organic framework nanoparticles; the liposome is used as a carrier and entraps the metal organic framework nano-particles, the mesenchymal stem cell exosome and the miR-204-3p which have a slow release characteristic. By integrating the advantages of the liposome, the exosome and the metal organic framework, the synergistic treatment of the MASLD is realized. According to the system, lipidosome is adopted as an intelligent carrier, MOF nanoparticles and mesenchymal stem cell exosomes with slow release characteristics are entrapped, and therapeutic miR-204-3p is loaded at the same time. The MOF material has functions of drug controlled release and active oxygen removal, and synergistically exerts anti-oxidation, anti-inflammatory and anti-fibrosis effects with the exosome and miRNA. The system has a pH response characteristic, and can intelligently release drugs in an acidic microenvironment of an MASLD focus to realize targeted treatment of the liver.

The invention provides a metabolism-related fatty liver disease prediction method based on a self-attention mechanism, and the method comprises the steps: obtaining blood test and four diagnosis instrument data of a patient, and constructing a fatty liver disease data set; according to the same index data of the same patient in different periods, adding time sequence information codes to form an optimized fatty liver disease data set with sequence features; constructing and training a fatty liver detection model, wherein the fatty liver detection model comprises a convolutional neural network, a layered attention module and a feedforward neural network layer; and inputting patient data into the trained fatty liver detection model to obtain the metabolism-related fatty liver disease prediction grade of the patient. According to the invention, the method achieves the refined reasoning of the time sequence indexes of the patient through multi-scale convolution and hierarchical attention, and improves the prediction precision of the model.

The invention discloses a composition capable of quickly dispelling the effects of alcohol and relieving moderate and mild fatty liver and application of the composition, and particularly relates to the technical field of health care products. The composition comprises the silybum marianum extract, the schisandra chinensis extract, the globe artichoke extract and the 1, 6-fructose diphosphate and cyclodextrin-clathrated silybum marianum extract as raw materials, on one hand, the bioavailability of the product is improved, the taste of the product is better, and the taste of the clathrated product is improved due to the fact that silybin is very bitter and cyclodextrin has a shielding property; and on the other hand, the FDP and the three plant extracts have a synergistic effect, and the combined composition can achieve the effects of quickly dispelling the effects of alcohol and relieving moderate and mild fatty liver.

The invention relates to a preparation method and application of a medicine-food homologous compound with weight-losing and lipid-lowering effects. According to the present invention, the weight of the obese mouse can be reduced by 23.23% at most, the serum total cholesterol is reduced, the leptin secretion is reduced, AST (aspartate transaminase) and ALT (alanine transaminase) have no significant difference compared to the model mouse, the volume of epididymal fat and inguinal fat cells is reduced, the number of cells in unit area is significantly increased, the fatty liver sample is relieved, the TMEM26 gene expression in the epididymal fat is significantly increased, and the weight of the obese mouse can be significantly reduced; the expression quantity of the UCP1 gene in brown fat is obviously increased. The traditional Chinese medicine composition adopts medicinal and edible substances as raw materials, is widely applicable to people, is more suitable for prevention and treatment of chronic diseases, is safe and effective, and causes little damage to liver and kidney after long-term use.

The invention relates to the field of medicines, and particularly discloses a fusion protein with a GIP and GLP-1 dual receptor agonist function and application of the fusion protein. A specifically designed GLP-1 / GIP targeting polypeptide is fused with the N end of an IgG4 heavy chain constant region and the N end of a light chain constant region or the N end of Fc to obtain the GLP-1 / GIP targeting polypeptide. A research result shows that the fusion protein with the GIP and GLP-1 dual receptor agonist function has an obvious effect of reducing the weight of a mouse, the weight of the liver of the mouse is also reduced, the blood sugar of the mouse is also remarkably reduced, and the total cholesterol in serum is reduced to a certain extent. Therefore, the compound can be applied to medicines or products for slimming, reducing blood sugar and treating fatty liver.